Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials

@article{Xu2019SafetyAT,
  title={Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials},
  author={Da Xu and Deng Chen and Lina Zhu and G. Tan and Hai-jiao Wang and Y. Zhang and L. Liu},
  journal={Cephalalgia},
  year={2019},
  volume={39},
  pages={1164 - 1179}
}
Aim To systematically evaluate the safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies from the results of randomized controlled trials. Methods Online databases were searched on calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine. Overall withdrawal, withdrawal due to adverse events, adverse events, serious adverse events and specific adverse events were extracted from the included studies. A meta-analysis… Expand
The role of erenumab in the treatment of migraine
Recent Advances in Pharmacotherapy for Episodic Migraine
...
1
2
...

References

SHOWING 1-10 OF 35 REFERENCES
Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis
...
1
2
3
4
...